Haemostatic alterations and management of haemostasis in patients with cirrhosis
- PMID: 35589251
- DOI: 10.1016/j.jhep.2021.11.004
Haemostatic alterations and management of haemostasis in patients with cirrhosis
Abstract
Patients with cirrhosis frequently acquire complex changes in their haemostatic system including a decreased platelet count and decreased levels of various haemostatic proteins. Although historically patients with cirrhosis were thought to have a haemostasis-related bleeding tendency, it is now widely accepted that the haemostatic system of patients with cirrhosis remains in balance as a result of simultaneous changes in pro- and anti-haemostatic systems. The concept of rebalanced haemostasis has led to changes in clinical management, although firm evidence from well-designed clinical studies is largely lacking. For example, many invasive procedures in patients with cirrhosis and a prolonged prothrombin time are now performed without prophylaxis with fresh frozen plasma. Conversely, clinicians have become more aware of the need for anti-thrombotic therapy, even in those patients with abnormal routine coagulation tests. This paper will outline recent advances in pathogenesis, prevention and treatment of both bleeding and thrombotic complications in patients with cirrhosis. Among other topics, we will discuss the haemostatic status of acutely ill patients with cirrhosis, the various causes of bleeding in patients with cirrhosis, and how best to prevent or treat bleeding. In addition, we will discuss the hypercoagulable features of patients with cirrhosis, new insights into the pathogenesis of portal vein thrombosis, and how best to prevent or treat thromboses.
Keywords: bleeding; coagulation; fresh frozen plasma; liver disease; platelets; portal vein thrombosis; thrombosis; variceal bleeding.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest TL has no conflicts of interest to report. NMI reports education grant support from Dova. SHC reports research sponsored trials (NASH, PBC, PSC) from Gilead, Madrigal, BMS, GenFit, Zydus, Galectin, Akero, Galmed, and Inventiva; Royalty for device from Avanos; Honoraria for Lectures from Houston Methodist, University Washington, Thomas Jefferson University; Grant support for Coagulation in Liver Disease meeting from Shionogi and Dova. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Enoxaparin is safe and effective for restoring and preserving forward portal venous flow in children with end-stage liver disease.J Hepatol. 2023 Feb;78(2):e57-e59. doi: 10.1016/j.jhep.2022.11.001. Epub 2022 Nov 9. J Hepatol. 2023. PMID: 36370953 No abstract available.
Similar articles
-
Pathophysiology and management of bleeding and thrombosis in patients with liver disease.Int J Lab Hematol. 2022 Sep;44 Suppl 1(Suppl 1):79-88. doi: 10.1111/ijlh.13856. Epub 2022 Apr 21. Int J Lab Hematol. 2022. PMID: 35446468 Free PMC article. Review.
-
Unravelling the coagulation paradox in liver cirrhosis: challenges and insights.Acta Clin Belg. 2024 Dec;79(6):451-461. doi: 10.1080/17843286.2025.2469906. Epub 2025 Feb 21. Acta Clin Belg. 2024. PMID: 39981790 Review.
-
Treatment of bleeding in patients with liver disease.J Thromb Haemost. 2021 Jul;19(7):1644-1652. doi: 10.1111/jth.15364. Epub 2021 Jun 6. J Thromb Haemost. 2021. PMID: 33974330 Free PMC article.
-
Rotational ThromboElastometry-guided blood component administration versus standard of care in patients with Cirrhosis and coagulopathy undergoing Invasive ProcEdures (RECIPE): study protocol for a randomised controlled trial.Trials. 2023 Aug 11;24(1):516. doi: 10.1186/s13063-023-07552-1. Trials. 2023. PMID: 37568228 Free PMC article.
-
Haemostasis in cirrhosis: Understanding destabilising factors during acute decompensation.J Hepatol. 2023 May;78(5):1037-1047. doi: 10.1016/j.jhep.2023.01.010. Epub 2023 Jan 25. J Hepatol. 2023. PMID: 36708812 Review.
Cited by
-
Predictive value of hematological parameters in cirrhotic patients with open umbilical hernia repair.Hernia. 2024 Feb;28(1):119-126. doi: 10.1007/s10029-023-02908-7. Epub 2023 Oct 17. Hernia. 2024. PMID: 37848581
-
An overview of downhill esophageal varices: a challenge for medical practice.Ann Med. 2025 Dec;57(1):2462452. doi: 10.1080/07853890.2025.2462452. Epub 2025 Feb 4. Ann Med. 2025. PMID: 39903475 Free PMC article. Review.
-
Pulmonary Embolism in Critically Ill Patients-Prevention, Diagnosis, and Management.Diagnostics (Basel). 2024 Oct 3;14(19):2208. doi: 10.3390/diagnostics14192208. Diagnostics (Basel). 2024. PMID: 39410612 Free PMC article. Review.
-
Assessment of the efficiency and safety of anti-coagulation therapy in patients with liver cirrhosis and atrial fibrillation.Clin Exp Hepatol. 2023 Sep;9(3):265-271. doi: 10.5114/ceh.2023.130605. Epub 2023 Aug 21. Clin Exp Hepatol. 2023. PMID: 37790690 Free PMC article.
-
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort.United European Gastroenterol J. 2024 Apr;12(3):352-363. doi: 10.1002/ueg2.12496. Epub 2023 Nov 30. United European Gastroenterol J. 2024. PMID: 38032175 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical